U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H16N4O
Molecular Weight 244.2923
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VELIPARIB

SMILES

C[C@@]1(CCCN1)C2=NC3=C(N2)C=CC=C3C(N)=O

InChI

InChIKey=JNAHVYVRKWKWKQ-CYBMUJFWSA-N
InChI=1S/C13H16N4O/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17)/t13-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17473206 | https://www.ncbi.nlm.nih.gov/pubmed/26251615

Veliparib (ABT-888) is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models. AbbVie is developing veliparib for the treatment of cancers. Clinical trials are underway worldwide, investigating veliparib primarily as part of a combination therapy in oncology indications such as brain, colorectal, melanoma, ovarian, prostate and pancreatic cancers.

CNS Activity

CNS Penetrant
2554
Curator's Comment: Veliparib is brain penetrant in rodents. No human data available but the drug is studying for treatment of brain tumors https://www.ncbi.nlm.nih.gov/pubmed/24908656 | https://www.ncbi.nlm.nih.gov/pubmed/25682091

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 5.2 nM [Ki]
Inhibitor
8297
 2.9 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
656
Unknown

Approved Use

Unknown
Primary
Phase III
656
Unknown

Approved Use

Unknown
Primary
Phase III
656
Unknown

Approved Use

Unknown
Primary
Phase III
656
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
800 mg 1 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
DLT: Seizure...
Dose limiting toxicities:
Seizure (grade 3, 33.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
400 mg 2 times / day multiple, oral
MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
unhealthy, ADULT
n = 9
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
DLT: Vomiting, Appetite decreased NOS...
Disc. AE: Fatigue, Vomiting...
Dose limiting toxicities:
Vomiting (grade 3, 8.3%)
Appetite decreased NOS (grade 3, 8.3%)
Fatigue (grade 3, 8.3%)
Nausea (grade 3, 8.3%)
AEs leading to
discontinuation/dose reduction:
Fatigue (25%)
Vomiting (16.7%)
Neutropenia (25%)
Nausea (25%)
Thrombocytopenia (25%)
Anemia (8.3%)
Essential tremor (8.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
600 mg 2 times / day multiple, oral
Studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
unhealthy, ADULT
n = 5
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
DLT: Asthenia, Nausea...
Dose limiting toxicities:
Asthenia (grade 2, 20%)
Nausea (grade 3, 20%)
Vomiting (grade 3, 20%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
AEs

AEs

AESignificanceDosePopulation
Seizure grade 3, 33.3%
DLT
800 mg 1 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
Vomiting 16.7%
Disc. AE
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Fatigue 25%
Disc. AE
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Nausea 25%
Disc. AE
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Neutropenia 25%
Disc. AE
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Thrombocytopenia 25%
Disc. AE
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Anemia 8.3%
Disc. AE
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Essential tremor 8.3%
Disc. AE
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Fatigue grade 3, 8.3%
DLT
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Nausea grade 3, 8.3%
DLT
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Vomiting grade 3, 8.3%
DLT
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Appetite decreased NOS grade 3, 8.3%
DLT, Disc. AE
400 mg 2 times / day multiple, oral
RP2D
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/28665051
Page: p.1836
Asthenia grade 2, 20%
DLT
600 mg 2 times / day multiple, oral
Studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
unhealthy, ADULT
n = 5
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
Nausea grade 3, 20%
DLT
600 mg 2 times / day multiple, oral
Studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
unhealthy, ADULT
n = 5
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
Vomiting grade 3, 20%
DLT
600 mg 2 times / day multiple, oral
Studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
unhealthy, ADULT
n = 5
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/29733524
Page: p.2365
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY103035
https://www.001chemical.com/chem/search?q=DY103035
1PlusChem LLC
1P003A1L
https://www.1pchem.com/search?query=1P003A1L
1PlusChem LLC
1P006PW0
https://www.1pchem.com/search?query=1P006PW0
A2B Chem
AB52185
http://a2bchem.com/prod/AB52185
A2B Chem
AD12688
http://a2bchem.com/prod/AD12688
AChemBlock
10404
http://www.achemblock.com/catalogsearch/result/?q=10404
AChemBlock
Q70244
http://www.achemblock.com/catalogsearch/result/?q=Q70244
AK Scientific
SYN5722
https://aksci.com/item_detail.php?cat=SYN5722
AK Scientific
X7540
https://aksci.com/item_detail.php?cat=X7540
AK Scientific
Y0314
https://aksci.com/item_detail.php?cat=Y0314
AOBIOUS INC
AOB87114
http://aobious.com/aobious/search?search_query=AOB87114
Angene
AGN-PC-0VRX87
http://www.angenechemical.com/productshow/AGN-PC-0VRX87.html
ApexBio Technology
A3958
https://www.apexbt.com/catalogsearch/result/?q=A3958
AstaTech
41373
http://astatechinc.com/CPSResult.php?CRNO=41373
AstaTech
41382
http://astatechinc.com/CPSResult.php?CRNO=41382
Axon MedChem
1593
https://www.axonmedchem.com/product/1593
Axon MedChem
2888
https://www.axonmedchem.com/product/2888
BLD Pharm
BD160254
http://www.bldpharm.com/search/Search.html?keyword=BD160254
BOC Sciences
912444-00-9
http://www.bocsci.com/description.asp?cas=912444-00-9
Cayman Chemical
11505
http://www.caymanchem.com/app/template/Product.vm/catalog/11505
Chem Scene
CS-0076
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0076
Chem Scene
CS-0077
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0077
ChemShuttle
100936
https://www.chemshuttle.com/catalogsearch/result/?q=100936
ChemShuttle
133768
https://www.chemshuttle.com/catalogsearch/result/?q=133768
Debye Scientific
DB-078941
https://www.debyesci.com/index.php?id=product&ext[cno]=DB-078941
Fluorochem
519795
http://www.fluorochem.co.uk/Products/Product?code=519795
KeyOrganics
AS-17023
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-17023
KeyOrganics
AS-19397
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-19397
KeyOrganics
STR12090
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=STR12090
Lab Network
LN01270977
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01270977
Lab Network
LN01325591
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01325591
Matrix Scientific
120689
http://www.matrixscientific.com/120689.html
Matrix Scientific
153553
http://www.matrixscientific.com/153553.html
MedChem Express
HY-10129
https://www.medchemexpress.com/search.html?q=HY-10129&ft=&fa=&fp=
MedChem Express
HY-10130
https://www.medchemexpress.com/search.html?q=HY-10130&ft=&fa=&fp=
MolPort
MolPort-009-679-436
https://www.molport.com/shop/molecule-link/MolPort-009-679-436
MolPort
MolPort-016-631-859
https://www.molport.com/shop/molecule-link/MolPort-016-631-859
MolPort
MolPort-016-633-168
https://www.molport.com/shop/molecule-link/MolPort-016-633-168
MolPort
MolPort-021-804-902
https://www.molport.com/shop/molecule-link/MolPort-021-804-902
MolPort
MolPort-027-720-945
https://www.molport.com/shop/molecule-link/MolPort-027-720-945
Molcore
MC103035
http://www.molcore.com/CatMC103035.html
Molnova
M16548
https://www.molnova.com/en/serch-list.html?keywords=M16548
Molnova
M16549
https://www.molnova.com/en/serch-list.html?keywords=M16549
MuseChem
I005438
https://www.musechem.com/product/I005438.html
MuseChem
I005439
https://www.musechem.com/product/I005439.html
Ryan Scientific
ABT888_HCL
https://ryansci.com/products?q=ABT888_HCL&list_q=&search_type=exact
Ryan Scientific
Histone_Deacetylase_Inhibitor_III
https://ryansci.com/products?q=Histone_Deacetylase_Inhibitor_III&list_q=&search_type=exact
Selleck Chemicals
S1004
http://www.selleckchem.com/search.html?searchDTO.searchParam=S1004
ShangHai Biochempartner
BCP000074
http://www.biochempartner.com/search_BCP000074
ShangHai Biochempartner
BCP01727
http://www.biochempartner.com/search_BCP01727
ShangHai Biochempartner
BCP09427
http://www.biochempartner.com/search_BCP09427
Toronto Research Chemicals
A112580
https://www.trc-canada.com/product-detail/?CatNum=A112580
eMolecules
271447500
https://orderbb.emolecules.com/search/#?query=271447500
eMolecules
295311079
https://orderbb.emolecules.com/search/#?query=295311079
eMolecules
32278019
https://orderbb.emolecules.com/search/#?query=32278019
eMolecules
36788386
https://orderbb.emolecules.com/search/#?query=36788386
eMolecules
43473183
https://orderbb.emolecules.com/search/#?query=43473183
eNovation Chemicals
D210761
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D210761&searchbtn.x=0&searchbtn.y=0
mcule
MCULE-1119640162
https://mcule.com/MCULE-1119640162/
mcule
MCULE-3543863580
https://mcule.com/MCULE-3543863580/
mcule
MCULE-3859998796
https://mcule.com/MCULE-3859998796/
mcule
MCULE-6745061181
https://mcule.com/MCULE-6745061181/
PubMed

PubMed

TitleDatePubMed
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
2007 May 1
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
2007 May 15
A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia.
2008 Aug
Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage.
2008 Jun
Patient perspectives on phase 0 clinical trials.
2008 Jun 15
Phase 0 trials: an industry perspective.
2008 Jun 15
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
2008 Nov 1
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
2008 Oct
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
2008 Oct 15
Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase.
2008 Sep 1
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
2008 Sep-Oct
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
2009 Feb
94th RSNA Annual Meeting.
2009 Jan
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
2009 Jan 22
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
2009 Jun 1
Phase 0 clinical trials: an answer to drug development stagnation?
2009 Jun 1
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.
2010
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
2010 Jul 1
Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
2010 Mar-Apr
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.
2010 Oct
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
2011 Apr 1
Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase.
2011 Jul
The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.
2011 Jun
Patents

Patents

20060229289
2
WO/2013/173428A1
1
WO/2016/044384A1
1

Sample Use Guides

In Vivo Use Guide
recommended Phase II dose of single-agent veliparib as 400 mg bid.
Route of Administration: Oral
In Vitro Use Guide
Using colon cancer cell lines significant synergy was observed between Veliparib (ABT-888) and irinotecan at concentrations of ABT-888 as low as 0.125 μM. The level of synergy observed correlated with the degree of PARP1 inhibition as measured biochemically in cell lysates. ABT-888 at concentrations of 0.5-4 μM resulted in synergy with oxaliplatin.
Name Type Language
VELIPARIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
PARP-1 INHIBITOR ABT-888
Code English
veliparib [INN]
Common Name English
Veliparib [WHO-DD]
Common Name English
1H-BENZIMIDAZOLE-7-CARBOXAMIDE, 2-((2R)-2-METHYL-2-PYRROLIDINYL)-
Systematic Name English
VELIPARIB [JAN]
Common Name English
ABT-888
Code English
VELIPARIB [USAN]
Common Name English
2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/10/830
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
FDA ORPHAN DRUG 542916
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
FDA ORPHAN DRUG 456514
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
NCI_THESAURUS C62554
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
FDA ORPHAN DRUG 257108
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
FDA ORPHAN DRUG 246607
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
FDA ORPHAN DRUG 295509
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
FDA ORPHAN DRUG 290209
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
Code System Code Type Description
PUBCHEM
11960529
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
FDA UNII
01O4K0631N
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
INN
9211
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
ChEMBL
CHEMBL506871
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
WIKIPEDIA
VELIPARIB
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
NCI_THESAURUS
C60768
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
CAS
912444-00-9
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
CHEBI
62880
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
DRUG BANK
DB07232
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
SMS_ID
100000124275
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
EPA CompTox
DTXSID90238456
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
USAN
WW-28
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
EVMPD
SUB32392
Created by admin on Fri Dec 15 17:15:31 GMT 2023 , Edited by admin on Fri Dec 15 17:15:31 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of VELIPARIB
METABOLITE LESS ACTIVE (PARENT)
Structure of Veliparib lactam metabolite
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966